Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 + — eChoVid  

Interstitial Pneumonia Clinical Trial

Official title: Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +

Status Completed

Clinical Trial Summary

The recent pandemic due to the SARS-CoV2 results in a pulmonary infection in major symptomatic patients. Because of the large number of patients and the risk of acute respiratory distress syndrome (which seems to occur in almost 5% of patients), there is a real challenge to improve physician ability to screen between patients those who will require specific surveillance and those who can be sent back home. The recent French official recommendation of the French radiology society prescribe that chest X-ray do not have any place in the COVID-19+ management whereas the WHO stipulate that ultrasound machines may be useful for these patients [1-2]. Moreover, scattered recent publications tend to stress the interest of quick ultrasound imaging for COVID-19 suspected patients for screening purpose [2-5].

The aim of this observational historico-prospective study is to assess the risk of severe clinical outcomes (admission in continuous care unit (USC), invasive respiratory assistance, death) in patients suspected or diagnosed COVID-19+ as a function of initial pulmonary ultrasound abnormalities. These clinical outcomes are assessed through phone calls at D5, D15, M1.

The secondary objectives are:

• Assessing the concordance between the severity of pulmonary lesions as detected by pulmonary ultrasound devices and the ones detected by CT-scanner, for patients who will undergo these two examinations.

• Assessing the compared performances in detecting ultrasound pulmonary lesions for patients suspected or diagnosed COVID-19+, between an experimented operator and a newly trained operator.

• Evaluate in suspected or COVID-19 patients, the risk of clinical worsening based on pulmonary ultrasound abnormalities during follow-up of hospitalized patients.

• Evaluate the ultrasound evolution profiles of pulmonary lesions in patients whose clinical evolution is favorable.

• Evaluate the incidence of thromboembolic events in patients who worsen secondarily.

Clinical Trial Description

The practitioners involved at each site are

• either emergency physicians who are experts in pulmonary ultrasound

• either newly trained doctors who have received 30 minutes quick training in the fundamentals of pulmonary ultrasound.

The data collected under this protocol consists in:

• data from clinical examination: blood pressure, heart rate, respiratory rate, saturation, signs of confusion, body temperature, calculation of the CRB65 and qSOFA score, date of onset of symptoms

• Former patient journey: home, hospital, nursing home, others

• Medical background

• Recent use in the context of NSAID symptomatology

• Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the context of a known pathology

• Results and date of PCR-Covid-19 test

• Pulmonary ultrasound results: quotation in 8 fields (right antero-superior, left antero-superior, right antero-inferior, left antero-inferior, right postero-superior, left postero-superior, right postero-inferior and postero-upper left).

• The operator's identity and level of expertise will be indicated.

Patients follow-up happens at D5, D15 and D28 through phone call. After verifying their identity using the initials entered and their date of birth, the patient or the referring person in the medical file is asked where the patient is currently (home, non ICU department, ICU department) and whether the patient is in respiratory assistance (invasive or not). In the event of notification of death, the date of occurrence will be indicated.

Patients are informed orally (in the event of altered state of consciousness, their close relative present will benefit from this information) that they will be contacted remotely (at D5, D15 and D28) to inquire about their development.

Patients hospitalized in most of the hospitals participating in the research will be offered a daily assessment of their clinical status, an ultrasound within 24-48 hours of the start of hospitalization, two other ultrasounds performed between D5 and D10. A final ultrasound will be performed before leaving the service.

In the event of worsening, a compression ultrasound of the lower limbs and a simple cardiac ultrasound is performed in search of signs of DVT or an acute pulmonary heart on a 4-point compression ultrasound and echocardiography which will be performed in the event of clinical worsening following the inclusion of the following :

• Evidence of a thrombus proximal to 4-point echo compression due to non-compressibility and / or absence of color doppler flow during a venous flushing maneuver

• Evidence of dilation of the ventricle Dt with VD / VG ratio> 1 or presence of a paradoxical septum.

• A search for the occurrence of one of these 3 events

• Addressing in intensive care units

• Mechanical ventilation

• Death. In the event of notification of death, the date of occurrence will be indicated.

The report of the examination will be given on a standardized examination sheet with identification of the patient on each examination + identifier of the clinician operator.

The data will be kept for remote reading by a referent. All these examinations are carried out as part of the management of patients for the treatment of their COVID infection.

Patients are also informed:

• that any new information arising during the participation to the study, which could possibly modify his non opposition to this very participation, will be given

• of the right to have communication of information, held by the investigators, concerning their health, during or at the end of the research.

• Results of the chest scanner: typical COVID-19 and extent of the damage (minimal, moderate, severe)

• Initial patient orientation: return home, simple hospitalization or continuous care unit (USC), with or without respiratory assistance (and of what type: invasive or non-invasive), death (date of death)

• Whether or not to take chloroquine (on D0, D5, D15 or D28)

• Patient follow-up: same data as during the initial orientation on day 0, day 5, day 15 and D28. ;

Related Conditions & MeSH terms

• 2019-nCoV (COVID-19)
• COVID-19
• Interstitial Pneumonia
• Lung Diseases, Interstitial

• NCT number: NCT04335019
• Study type: Observational
• Source: Assistance Publique - Hôpitaux de Paris
• Status: Completed
• Start date: April 2, 2020
• Completion date: May 26, 2020